Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Human coronavirus NL63 3C-like proteinase (3CLpro), also known as the main protease (Mpro) or nsp5, is a critical enzyme for the replication and transcription of the HCoV-NL63 virus [1, 3]. It is a cysteine protease that functions as a homodimer to cleave the large viral replicase polyproteins (pp1a and pp1ab) at eleven distinct sites, releasing essential non-structural proteins required for the viral life cycle [1, 4]. HCoV-NL63 is a common human respiratory pathogen associated with a range of illnesses, from the common cold to more severe conditions such as croup, bronchiolitis, and pneumonia, particularly in children and immunocompromised individuals [2, 3, 12]. Because of its indispensable role in the viral life cycle and its high conservation across the Coronaviridae family, 3CLpro is a primary target for the development of broad-spectrum antiviral drugs [3, 5, 8]. Inhibitors such as MK-7845 and GC376 target the catalytic cysteine residue within the enzyme's active site, effectively blocking viral replication [5, 8]. While no specific 3CLpro inhibitors are currently approved specifically for HCoV-NL63, the enzyme's unique substrate specificity—recognizing a glutamine residue at the P1 position—makes it an attractive target with potentially low off-target effects on host cell proteases [5].
Inhibition of the viral 3C-like protease, which prevents the cleavage of the replicase polyproteins pp1a and pp1ab, thereby blocking the production of functional non-structural proteins essential for viral replication and transcription [1, 3, 5].
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human coronavirus NL63 3C-like proteinase (3CLpro) (3CLpro).